SBC Medical Group Holdings Incorporated SBC R2K
Company Overview
SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement. It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers. In addition, the company offers surgical and non-surgical surgeries that include breast augmentation; liposuction; rejuvenation treatments, such as treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. Further, it owns and operates treatment centers under the SBC brand. SBC Medical Group Holdings Incorporated was founded in 2000 and is headquartered in Irvine, California.
Why Investors Should Care
Generates a return on equity of 18.9%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.1%.
Net profit has compounded at 13.8% per year over the last five years.
Trades at a P/E of 11.0, below the sector median of 25.6.
Maintains a net profit margin of 28.0%.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Dec 2025 Revenue of $173.61M (-15.5% YoY); net profit $50.99M.
- Trailing 12 Months Year-on-year growth — revenue +13.4%, earnings +338.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.3%, profit CAGR 13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.29% |
| 1 Year: | 13.40% |
Compounded Profit Growth
| 5 Years: | 13.80% |
| 1 Year: | 338.90% |
Stock Price Performance
| 1 Year: | +22.36% |
| 6 Months: | +57.61% |
| 3 Months: | +65.52% |
| 1 Month: | +11.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.92 · Neutral
P/E of 11.00 is below the sector median of 25.60 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.1%.
- Excellent profit margin of 28.0%.
- Profit CAGR of 13.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -5.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Industrials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SBC SBC Medical Group Holdings Incorporated R2K | 5.28 | 11.00 | $543.03M | 0.00% | 21.13% | 18.91% | -5.29% | 13.80% |
| 2 | SPCX Space Exploration Technologies Corp. R3KAIDEFENCE | 147.49 | -134.08 | $1.12T | 0.00% | -3.22% | -11.95% | 34.08% | -3.34% |
| 3 | CAT Caterpillar Inc. SPXR3K | 687.00 | 29.57 | $315.80B | 0.80% | 17.98% | 56.97% | 2.29% | 5.24% |
| 4 | GE GE Aerospace SPXR3KDEFENCE | 285.64 | 33.60 | $296.37B | 0.60% | 9.52% | 48.23% | -7.42% | -5.36% |
| 5 | RTX RTX Corporation SPXR3KDEFENCE | 191.01 | 33.69 | $257.44B | 1.51% | 8.28% | 12.27% | 2.61% | 2.62% |
| 6 | GEV GE Vernova Inc. SPXR3KAI | 815.00 | 23.37 | $217.06B | 0.22% | 6.30% | 82.58% | 8.68% | - |
| 7 | DE Deere & Company SPXR3K | 646.15 | 37.74 | $174.22B | 0.99% | 12.53% | 18.24% | 3.43% | 5.10% |
| 8 | UNP Union Pacific Corporation SPXR3K | 292.87 | 23.73 | $173.99B | 2.01% | 15.22% | 39.70% | 2.30% | 7.77% |
| 9 | BA The Boeing Company SPXR3KDEFENCE | 188.35 | 67.27 | $148.76B | 0.00% | -9.01% | - | 1.67% | -3.28% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 47.28M | 54.81M | 53.10M | 53.08M | 47.33M | 43.36M | 43.35M | 43.06M |
| Gross Profit | - | - | - | - | 33.50M | 39.52M | 39.42M | 43.24M | 37.73M | 30.01M | 30.61M | 30.35M |
| Operating Income | -1.28K | -303.62K | -388.45K | -473.37K | 20.02M | 24.46M | 27.29M | 13.83M | 24.20M | 14.55M | 15.88M | 17.72M |
| Net Income | -1.28K | -11.42K | 613.33K | 196.79K | 8.36M | 18.76M | 18.48M | 2.83M | 21.50M | 2.46M | 12.82M | 11.31M |
| Diluted EPS | - | - | - | - | 0.09 | 0.20 | 0.20 | 0.03 | 0.21 | 0.02 | 0.12 | 0.11 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 193.54M | 205.42M | 173.61M |
| Gross Profit | 137.30M | 156.05M | 127.28M |
| Operating Income | 70.66M | 70.30M | 67.49M |
| Net Income | 39.37M | 46.61M | 50.99M |
| Diluted EPS | 0.42 | 0.48 | 0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 119.94M | 258.81M | 266.08M | 380.45M |
| Total Equity | -3.36M | 142.16M | 195.11M | 248.28M |
| Cash & Equivalents | 485.56K | 103.02M | 125.04M | 163.77M |
| Long Term Debt | - | - | 6.60M | 42.83M |
| Total Liabilities | 4.59M | 115.00M | 71.06M | 117.14M |
| Current Liabilities | 566.01K | 92.45M | 61.19M | 61.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 50.67M | 20.58M | 24.67M |
| Investing Cash Flow | 1.79M | -10.10M | -20.97M |
| Financing Cash Flow | 6.14M | 22.97M | 38.29M |
| Capital Expenditure | -8.54M | -2.56M | -1.40M |
| Free Cash Flow | 42.13M | 18.02M | 23.27M |
| Share Buybacks | - | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 70.9% | 76.0% | 73.3% |
| Operating Margin % | 36.5% | 34.2% | 38.9% |
| Net Margin % | 20.3% | 22.7% | 29.4% |
| ROE % | 27.7% | 23.9% | 20.5% |
| ROCE % | 42.5% | 34.3% | 21.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lumbard & Kellner, LLC | 1.68% | 1.73M | $9.36M |
| 2 | Blackrock Inc. | 0.90% | 924.00K | $5.01M |
| 3 | Geode Capital Management, LLC | 0.42% | 427.86K | $2.32M |
| 4 | Citadel Advisors Llc | 0.14% | 144.72K | $784.37K |
| 5 | Vanguard Capital Management LLC | 0.13% | 135.78K | $735.94K |
| 6 | Northern Trust Corporation | 0.13% | 131.20K | $711.12K |
| 7 | Hillsdale Investment Management Inc. | 0.12% | 124.80K | $676.42K |
| 8 | Vanguard Portfolio Management LLC | 0.12% | 128.29K | $695.36K |
| 9 | Segall Bryant & Hamill, LLC | 0.08% | 81.31K | $440.68K |
| 10 | Vanguard Fiduciary Trust Co | 0.06% | 66.28K | $359.24K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SBC
A DNA test could track biological age as habits change. SBC Medical has begun developing one. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPUElVSDRvVnczNnM0ckpPSWdudVVoSXMxMlAzNGRuQTJENUZsLWRjRHM2T1dSU2M0alNTQncwdmszeklaSmRFcjhFVG9xMW0xYzZGRmZQTlBTY1UwWFN5VmZDS2lPaUtPX1RheTR0clhoLVZ4V0M1MVRZelZlTXVVeTBEdDgtREdhSS0zRF…
Johnson's Journal - SBC Media Day Stock Report; Trojans Trending Up - Troy University Athletics
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQTnNmQ3hxdk5oV0huaXIzUlpYZzRCTUhLY0FqaUdrOTRkUzBGNTJnQ0tGUGdveG9ERldoM0tXX2F4d0xaT1hQYlVLMnpCQ2czSTM1WXJjbUUwOHJPRGhNQndRNEtiM2d1d2xJUmZVZ09BbVVWVk9XdFhYNWFWQ012TjRIMG51Rk81X2lPVl…
Sabra Health Care REIT Inc (SBC.SG) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE9iMnJZeUVXV3lWSFdRTTExX1pjbm0yenJqYTRPOUYxd2M3X1NkV21UaUJLYjA4c1BoUE42ZEZtcTEzb3dxN2xKN0Y5NEtlZS1kSGtsUEZOSmVpdzA3cDkzbFluVWIxalZs?oc=5" target="_blank">Sabra Health Care REIT Inc …
Dentons Tax Update – Singapore: Transfer pricing treatment of stock-based compensation - Dentons
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWjVPaTBILUc2aEdFQmNTRU5PNjB5aVlMaW0yMUtaN1JCWkhfbXd2T2NkQmpLSS1JUmkxVm1fYkR3Z3FwRkd0c2tiU3RQU0gycHVjalFoaDQ3ZG9FbXVJM1BPT1RwNXlDYVkxWVdIX1RpcXM0ZndyRmNScGNnaTlKOHd6TVBNclpqLWRFbF…
(SBC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPZFk5cEVpZ1hRY3hrcnZrOTU0NmdIV1Y3WS1Ha1FxNkRJSHFwYzdpZUN5TGlHT2RVM3c5SmJ6QUdUeUFZNXRrenRrd3RPMVowRUt2dWl4RVU2cnRSVG5ybDRYaS1pblBGcGdqei1aQmVlQzltc3l5T1dBWDAtS3V3bUdUTkhPdmJoTWJHMl…
Snowflake Stock – The SBC Elephant in the Room - Nanalyze
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOd3p3SGtMRGoxZEI3U1dkSGRFR3h0M2tOWmRodThtVGpsZmlfMXpELVliYVNEcWM3NHBiYWxfaURKNVZwUHNEVlRBNV9CSGlCaVJjZ3duRG9ZTFU3UFJNcXVWRmtQa2FNLVBZdkhSWWJROFdvYWVwNGNyUnBHaTN3d0ZCLWI?oc=5" targ…
SBC — Frequently Asked Questions
What is the current share price of SBC Medical Group Holdings Incorporated (SBC)?
As of 2026-10-23 16:27 PDT, SBC Medical Group Holdings Incorporated (SBC) trades at $5.28 on NasdaqGM. Its 52-week range is $2.87 to $5.69.
What is the market capitalisation of SBC?
SBC Medical Group Holdings Incorporated (SBC) has a market capitalisation of $543.03M on NasdaqGM.
What is the P/E ratio of SBC?
SBC trades at a trailing price-to-earnings (P/E) ratio of 11.00. The industry average P/E is 25.60. Its price-to-book (P/B) ratio is 1.85.
What is the return on equity (ROE) of SBC?
SBC has a return on equity (ROE) of 18.91%. Its return on capital employed (ROCE) is 21.13%.
Is SBC a good stock to buy?
This page provides a data-driven analysis of SBC Medical Group Holdings Incorporated (SBC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.